Literature DB >> 17644672

Toxic shock syndrome in burns: diagnosis and management.

Amber E Young1, Katharine L Thornton.   

Abstract

Toxic shock syndrome (TSS), a toxin-mediated disease, is the most common cause of unexpected mortality in children with small burns. It is a diagnosis that is often missed because of non-specific signs and an ability to mimic other childhood illnesses. Any child with a pyrexia greater than 38.9 degrees C, a rash, or a sudden change in clinical condition within a few days of a burn injury should be monitored closely for TSS. If there is co-incident hyponatraemia or lymphopaenia, or if there is any deterioration in clinical condition, the child should be managed with anti-staphylococcal and streptococcal antibiotics and passive immunity for toxins provided by fresh frozen plasma (FFP) or intravenous immunoglobulin (IVIG). It is essential that all paediatric and emergency departments accepting children with burns are aware of the symptoms, signs and early management of TSS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17644672     DOI: 10.1136/adc.2006.101030

Source DB:  PubMed          Journal:  Arch Dis Child Educ Pract Ed        ISSN: 1743-0585            Impact factor:   1.309


  3 in total

1.  [Toxic shock syndrome (TSS) after a postsurgery knee infection].

Authors:  M de Jesus Pereira; K Jäckle
Journal:  Orthopade       Date:  2010-11       Impact factor: 1.087

2.  Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation.

Authors:  Mary Hongying Cheng; She Zhang; Rebecca A Porritt; Magali Noval Rivas; Lisa Paschold; Edith Willscher; Mascha Binder; Moshe Arditi; Ivet Bahar
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-28       Impact factor: 11.205

3.  An insertion unique to SARS-CoV-2 exhibits superantigenic character strengthened by recent mutations.

Authors:  Mary Hongying Cheng; She Zhang; Rebecca A Porritt; Moshe Arditi; Ivet Bahar
Journal:  bioRxiv       Date:  2020-05-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.